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Abstract
Specific oxidized phospholipids (oxPCCD36) promote platelet hyper-reactivity and thrombosis in hyperlipidemia via the
scavenger receptor CD36, however the signaling pathway(s) induced in platelets by oxPCCD36 are not well defined. We have
employed mass spectrometry-based tyrosine, serine, and threonine phosphoproteomics for the unbiased analysis of
platelet signaling pathways induced by oxPCCD36 as well as by the strong physiological agonist thrombin. oxPCCD36 and
thrombin induced differential phosphorylation of 115 proteins (162 phosphorylation sites) and 181 proteins (334
phosphorylation sites) respectively. Most of the phosphoproteome changes induced by either agonist have never been
reported in platelets; thus they provide candidates in the study of platelet signaling. Bioinformatic analyses of protein
phosphorylation dependent responses were used to categorize preferential motifs for (de)phosphorylation, predict
pathways and kinase activity, and construct a phosphoproteome network regulating integrin activation. A putative
signaling pathway involving Src-family kinases, SYK, and PLCc2 was identified in platelets activated by oxPCCD36.
Subsequent ex vivo studies in human platelets demonstrated that this pathway is downstream of the scavenger receptor
CD36 and is critical for platelet activation by oxPCCD36. Our results provide multiple insights into the mechanism of platelet
activation and specifically in platelet regulation by oxPCCD36.
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Introduction
Dyslipidemia is associated with oxidative stress and platelet
hyper-reactivity, a condition that increases the risk of thrombotic
complications in cardiovascular pathologies [1,2]. Evidence
suggests that oxidative stress in dyslipidemia promotes accumula-
tion of specific oxidized phospholipids in circulation, leading to
increased platelet activation responses and contributing to a
prothrombotic state. Biologically active oxidized phospholipids are
present in oxidized lipoproteins, apoptotic cells, atherosclerotic
lesions, and they accumulate in significant amounts in circulation
[3–6]. Oxidized choline glycerophospholipids are markedly
increased in plasma of hyperlipidemic mice and in plasma of
subjects with low HDL level, and promote platelet activation and
hyper-reactivity [3]. Selective removal of oxidized phospholipids
from plasma prevents platelet reactivity [7], providing further
evidence for their contribution to platelet hyper-reactivity in
dyslipidemia.
We previously showed that the scavenger receptor CD36 is the
major receptor on platelets that promotes platelet reactivity in
hyperlipidemic conditions in response to oxidized phospholipids
[3]. In vitro, CD36 mediates platelet activation by a group of
specific oxidized phospholipids (oxPCCD36) derived from the
oxidation of 1-palmitoyl-2-arachidonyl-phosphatidylcholine
(PAPC) and 1-palmitoyl-2-linoleoyl-phosphatidylcholine (PLPC).
Electrostatic interaction of the negatively charged carboxylate at
sn-2 position of oxPCCD36 with lysine [8,9] and covalent binding
of the electrophilic phospholipid to cysteine, lysine, or histidine
residues [10,11] serve as the basis for the recognition of oxidized
phospholipids by CD36 and other proteins. Although the receptor
responsible for platelet activation by oxidized phospholipids and
the binding mechanism are established, very little is known
regarding the signaling pathways downstream of CD36 in
platelets. Some progress has been made in the signaling
mechanisms initiated by oxidized LDL (oxLDL) in platelets
[12,13]. However, oxLDL contains a complex mixture of agonists
(i.e. oxPCCD36, amyloid-like structures, lysophosphatidylcholine,
oxysterols, PAF receptor activating-oxidized lipids) that can lead to
the activation of several independent signaling mechanisms [14–
17]. Given the important role of oxidized phospholipids in platelet
hyper-reactivity, it is essential to establish the specific signaling
mechanism(s) that control platelet activation by these ligands.
Phosphoproteomic studies are particularly useful in recognizing
platelet signaling mechanisms, since genomic approaches are
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limited in anucleated cells. Currently, phosphoproteomics based
on mass spectrometry provide the most comprehensive analysis for
identification and quantitation of phosphorylation sites from
diverse biological samples [18–20]. We have previously employed
a phosphoproteomic protocol based on the digestion of protein
lysate, enrichment of phosphopeptides in solution, and identifica-
tion of peptides by liquid chromatography-tandem mass spec-
trometry to study changes in protein phosphorylation induced by a
complex mixture of oxidized products of PAPC in aortic
endothelial cells [21]. Results from this study showed phosphor-
ylation-dependent responses of over 220 proteins and provided
new evidence for the participation of the receptor tyrosine kinase
VEGFR2 in the regulation of pro-inflammatory and coagulation
genes by oxidized phospholipids in endothelial cells [22]. In the
current study, we compared changes in phosphorylation between
platelets activated by oxidized phospholipids to platelets activated
by the strong agonist thrombin, in order to establish common and
differential signaling mechanisms. Thus, our study on phosphor-
ylation-dependent responses in platelets adds new information to
protein function in platelet homeostasis and disease. Our
phosphoproteomic results led us to construct the phosphopro-
teome network regulating integrin activation, and to determine
that the pathway Src-family kinase, Spleen tyrosine kinase, and
phospholipase PLCc2 is responsible for platelet activation by
oxidized phospholipids.
Materials and Methods
Materials
Prostaglandin I2 (PGI2) sodium salt, Sepharose 2B, BSA,
DMSO, and U73122 were purchased from Sigma-Aldrich (St
Louis, MO). Human a-thrombin was from Enzyme Research
Laboratories (South Bend, IN) and ADP from Chrono-log
(Havertown, PA). PE-conjugated anti–P-selectin antibody was
obtained from Becton Dickinson (San Jose, CA) and mouse anti-
CD36 (clone FA6-152) was purchased from Beckman Coulter
(Brea, CA). PP2, PP3, PD98059, and BAY61-3606 were obtained
from EMD Millipore (Billerica, MA). PLPC (1-palmitoyl-2-
linoleoyl-sn-glycero-3-phosphocholine) was from Avanti Polar
Lipids (Alabaster, AL). KODA-PC (9-keto-12-oxo-10-dodecenoic
acid ester of 2-lyso-phosphocholine) was synthesized as described
previously [23]. PLPC and KODA-PC were resuspended in
Tyrode’s buffer (without BSA and glucose) to prepare a 500 mM
stock solution just before the incubation with platelets as described
previously [5].
Ethics statement
All experiments done with human blood were approved by the
Cleveland Clinic’s Institutional Review Board. Written informed
consentwas obtained in accordancewith theDeclaration ofHelsinki.
Platelet isolation
Human venous blood was drawn from healthy donors into acid-
citrate-dextrose solution (ACD; 85 mM tri-sodium citrate, 65 mM
citric acid, and 111 mM D-glucose; pH 4.6). PGI2 was added after
blood collection into ACD to a final concentration 0.1 mg/mL.
Platelet-rich plasma (PRP) was separated by centrifugation at
150 g (15 min, 22uC). Platelets were pelleted from PRP by
centrifugation at 930 g (10 min, 22uC), resuspended in Tyrode’s
buffer (137 mM NaCl, 12 mM NaHCO3, 2.5 mM KCl, 10 mM
HEPES, 0.1 % BSA, 0.1 % glucose, pH 7.4), and further purified
by gel filtration using a Sepharose 2B column. The concentration
of platelets was determined using Cellometer M10 (Nexcelom
Bioscience, Lawrence, MA) and adjusted to concentrations
indicated with Tyrode’s buffer. CaCl2 and MgCl2 were added to
a final concentration of 2 mM and 1 mM, respectively, for
phosphoproteomic and flow cytometry experiments.
Phosphoproteomic and bioinformatic analysis of human
platelets
Human platelets isolated by gel filtration (2.76108/mL) were
incubated in Tyrode’s buffer with 50 mM KODA-PC or PLPC (as
control) for 30 min at 37uC. Platelets were then centrifuged at
3,700 g (10 min, 35uC) and lysed in 8 M urea, 50 mM Tris-HCl
(pH 7.4), 1 mM Na3VO4, and 1 mM NaF with sonication.
Phosphoproteome changes induced by the agonist from a single
biological experiment were assessed based on trypsin digestion of
the protein lysate, phosphopeptide enrichment, mass spectrometry
analysis, chromatography alignment, quantitation, and bioinfor-
matics and enrichment analysis as described in Materials and
Methods S1 and in our previous publications [21,24]. The same
protocol was applied when studying platelet activation by thrombin,
where gel-filtered platelets were incubated in Tyrode’s buffer with
0.05 U/mL thrombin or in buffer alone (Resting) for 3 min at
37uC. The mass spectrometry proteomics data have been deposited
to the ProteomeXchange Consortium (http://proteomecentral.
proteomexchange.org) via the PRIDE partner repository [25] with
the dataset identifier PXD000451. Annotated spectra can be found
in Annotated Spectra S1, Annotated Spectra S2, Annotated Spectra
S3, Annotated Spectra S4, and Annotated Spectra S5.
Immunoblotting
Platelets isolated by gel filtration (26108/mL) and treated with
indicated inhibitors and agonists were pelleted at 960 g (5 min,
37uC). The platelets were then lysed for 30 min on ice with
50 mM Tris-HCl (pH 7.4), 1 % IGEPAL CA-630, 0.25 % sodium
deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mg/
mL aprotinin, 1 mg/mL leupeptin, 1 mg/mL pepstatin, 1 mM
Na3VO4, and 1 mM NaF. Proteins were separated by SDS-
PAGE, transferred to PVDF membranes, and probed with rabbit
anti-human phospho-PLCc2 Tyr759, phospho-PLCc2 Tyr1217,
phospho-SYK Tyr323, phospho-SYK Tyr525/526 (C87C1), or
phospho-Src family Tyr416 (Cell Signaling, Danvers, MA). The
membranes were stripped and then probed for normalization with
rabbit anti-human SYK (C-20) (Santa Cruz Biotechnology, Santa
Cruz, CA) or PLCc2 (Cell Signaling).
Flow cytometry analysis
Human platelets isolated by gel filtration (26107/mL) were
incubated in Tyrode’s buffer with the indicated inhibitors for
30 min and then with agonists for another 30 min. Platelets were
incubated with PE-conjugated anti–P-selectin antibody and then
fixed with 2 % formaldehyde in PBS. Data was acquired using a
FACSCalibur instrument (Becton Dickinson, San Jose, CA) and
analyzed using FlowJo (Tree Star, Ashland, OR). Data are
presented as mean 6SD. Significant changes were determined
using one-way ANOVA with Bonferroni post-test. Significance
was accepted at the level of P,0.05.
Results
System-wide phosphoproteomic analysis of platelets
activated by the oxidized phospholipid KODA-PC and
thrombin reveals common and differential signaling
events
oxPCCD36 represent a family of oxidized choline glyceropho-
spholipids accumulating in vivo in dyslipidemia and oxidative stress
Platelet Activation by oxPCCD36 and Thrombin
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that possess several proatherogenic properties, including platelet
activation [3]. We investigated the signaling pathways induced by
oxPCCD36 in platelets using KODA-PC as one of the most
abundant and active representatives of the oxPCCD36 family [3].
Initial immunoblotting studies using pan-specific anti-phosphotyr-
osine and phospho-serine PKC substrate antibodies detected
changes in protein phosphorylation induced by KODA-PC in
isolated human platelets (Figure S1 in File S1). For further
comprehensive investigation of protein phosphorylation, we
employed a label-free phosphoproteomic approach based on the
enrichment of relatively less abundant phosphopeptides, followed
by identification and quantitation by liquid chromatography-
tandem mass spectrometry (Figure 1). In parallel, we performed
phosphoproteomic analysis of platelets activated by the strong
physiological agonist thrombin and compared signaling events
induced by both agonists. Using this approach, we identified 853
unique phosphorylation sites for 418 proteins in platelets. All
phospho-tyrosine/serine/threonine peptides identified are listed in
Table S1 in File S2. A comparison of our data and a study on
platelet protein composition [26] demonstrates the capability of
the approach we used to detect phosphorylation in proteins with
wide range of abundance (Figure S2 in File S1 and Table S2 in
File S2). Cellular localization of these proteins includes cytosol
(23%), plasma membrane (21%), cytoskeleton (25%), and secre-
tory granules (4%). Among the proteins identified, there were 46
with protein kinase activity and 12 with phosphatase activity.
KODA-PC induced significant increased or decreased phos-
phorylation ($1.5 fold change) of 162 sites in 115 proteins.
KODA-PC induced changes are reported here for the first time.
Thrombin induced significant (de)phosphorylation of 334 sites of
181 proteins. Direct comparison of phosphorylation sites found in
both sets of experiments indicate that many phosphorylation
events induced by KODA-PC and thrombin are similar in their
trend, although the fold increase was generally higher for
thrombin (Figure 2A). There were, however, notable differences
at specific sites (Figure 2B). For instance, Tyr508 in LYN is
dephosphorylated after platelet activation by KODA-PC, but not
by thrombin. This site is relevant in the kinase function because its
dephosphorylation allows for enzyme activation [27]. In contrast,
KODA-PC induced phosphorylation of LY6G6F at Tyr281, while
thrombin induced dephosphorylation. A previous report showed
phosphorylation of this site is induced by CRP and collagen but
not ADP or thrombin [28], and thus it could be an indicator for
differential regulation of platelet activation by KODA-PC. There
are common functional annotations for some of the proteins with
at least one site differentially phosphorylated (Figure 2B). In the
case of KODA-PC, we found differential phosphorylation sites on
proteins associated with actin or microtubules organization
(LIMA1, MAP4, TWF2, CASS4, SPAST, CTTN, and NEXN),
likely reflecting changes in organization of cytoskeleton induced
specifically by oxPCCD36. Thrombin differentially phosphorylated
sites on a number of proteins containing a pleckstrin homology
(PH) domain (BTK, ASAP1, FRMD4B, DOK1, DOK2, DAPP1,
FERMT3, and TEC). Since recognition of phosphoinositides is a
major function of PH-domains, this finding probably reflects a
major role for PI-3-kinase pathway in platelets activated by
thrombin as compared to KODA-PC.
Consensus motifs extracted from either phosphorylation or
dephosphorylation events induced by each agonist indicated the
presence of known kinase activities and binding targets (Table 1
and Figure S3 in File S1) [29,30]. For KODA-PC, two
phosphoserine motifs were enriched: RXXs (PKA and PKC
substrate motifs) and sP (Pro-directed, ERK 1/2 substrate motifs,
and WW domain binding motif). An additional phosphothreonine
motif, PXXXt which has not been described before, was enriched
in KODA-PC activated platelets. In thrombin activated platelets,
in addition to RXXs and sP motifs, other motifs were present
including y[E/D] (Src kinase substrate motif), RXXsL, PxsP
(GSK-3, ERK 1/2, CDK5 substrate motif), and tP (WW domain
binding motif). Two enriched motifs were extracted from
dephosphorylation events induced by thrombin, sP and sXXN.
We used a phosphorylation-dependent response as a gene input
to identify candidate signaling components with a direct role in
platelet activation by oxPCCD36 and thrombin by KEGG-
pathway, GO-term, and Kinase Enrichment Analysis (KEA)
[31] (Figure S4 in File S1 and Table S3, Table S4, and Table S5
in File S2). Most KEGG pathways identified in KODA-PC
activated platelets were also observed in thrombin and point to
important changes in platelet cytoskeleton. Thrombin, on the
other hand, induced pathways not detectable by KODA-PC, such
as MAPK signaling. As expected, GO-terms for cellular compart-
ments confirm that upon platelet activation, many of the
phosphoproteome changes take place in the plasma membrane,
cytoskeleton, and cell junctions associated with an alteration in
their morphology. Unique to KODA-PC was the enrichment of
the GO-term ‘‘actin filament binding’’, implicating specific
changes in cytoskeletal organization induced by KODA-PC.
Similar to KEGG-pathway analysis, KEA resulted in an overlap in
inferred activated kinases between KODA-PC and thrombin, with
additional kinases predicted in thrombin-induced platelets.
Phosphoproteomic network regulating integrin
activation in platelets activated by thrombin
We combined phosphoproteomic data from platelets activated
by thrombin (Table S1 in File S2) with a protein-protein
interaction database centered on integrins (integrin adhesome)
[32] to gain new information on key regulatory events in platelet
activation. We detected by mass spectrometry the phosphorylation
of 42 out of the 157 members that constitute the integrin
adhesome, and 35 of these proteins had at least one site
(de)phosphorylated ($1.5 fold change) in response to platelet
activation by thrombin (Figure 3). Among the phosphoproteome
changes, we observed (de)phosphorylation of proteins that directly
bind to the cytoplasmic tail of integrin b3 and, directly or
indirectly, regulate integrin signaling (Table 2). Among these
adaptors, talin (TLN1), filamin (FLNA), and kindlin-3 (FERMT3)
are key to regulate integrin inside-out signaling. Sites of
phosphorylation induced by thrombin in talin are located in the
FERM domain (Tyr127), vinculin binding site (Tyr1116), and rod
domain (Tyr1777). The function of the two phosphorylation sites
induced by thrombin in filamin is not known and one of them
(Ser1967) has never been described in any cell type. Finally, nearly
all observed changes in phosphorylation in kindlin-3 occurred in
the FERM domain regulating the membrane localization and
integrin binding.
Platelet activation by KODA-PC is mediated through the
SFK-SYK-PLCc2 pathway
Closer inspection of the phosphoproteomic data from platelets
activated by KODA-PC pointed to a small number of pathways
that could account for an activation mechanism. Among the
KEGG pathways with the highest enrichment value was Fc epsilon
RI signaling, a pathway known to initiate platelet activation (Table
S3 in File S2). In addition, some of the predicted activated kinases
with enrichment P-values ,0.05 (SYK, LYN, MYLK, and
PRKG1; Table S5 in File S2) were themselves found in KODA-
PC induced phosphorylation targets directly detected by mass
Platelet Activation by oxPCCD36 and Thrombin
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spectrometry (Table S1 in File S2). Interestingly, there was a clear
difference between KODA-PC and thrombin in the dephosphor-
ylation of Tyr508 of LYN (Table S1 in File S2). A single point
mutation at this site increases the basal level of phosphorylation in
SYK and PLCc2 in B cells [33]. We also detected a strong
phosphorylation of PLCc2, a substrate of SYK kinase, at Tyr1217
in response to KODA-PC (Table S1 in File S2). PLCc2
synthesizes IP3 and diacylglycerol critical for platelet activation.
Previous reports using ligands unrelated to oxPCCD36 have
demonstrated the critical role in platelet activation of a signaling
pathway, which includes the sequential activation of SFK, SYK,
and PLCc2 [34,35]. Taken together, our bioinformatics analysis,
mass spectrometry data, and previous reports on initiation of
platelet activation implicate the pathway SFK-SYK-PLCc2 as a
strong candidate for follow up in vitro studies in KODA-PC
mediated activation of platelets.
Activation of SFK, SYK, and PLCc2 is essential for KODA-
PC induced platelet P-selectin expression
We next used pharmacological inhibitors to assess the role of
SFK, SYK, and PLCc2 in platelet activation by KODA-PC.
Inhibitors of SFK (PP2), SYK (BAY61-3606), and PLC (U73122)
completely prevented P-selectin surface expression induced by
KODA-PC in human platelets (Figures 4A, 4B, and Figure S5 in
File S1). PP3, an inactive analog of PP2, had no effect. In contrast,
SFK and SYK inhibitors had no effect on platelet P-selectin
expression induced in platelets by weak physiological agonist ADP
or strong physiological agonist thrombin, both G-protein coupled
receptor agonists (Figure 4B). On the other hand, PLC inhibitor
U73122 suppressed P-selectin expression induced by all the
agonists tested (Figure S5 in File S1). Thus, KODA-PC, ADP,
and thrombin converge on the production of the second
messengers IP3 and DAG through different upstream signaling
mechanisms. The activation of macrophages by oxPCCD36
depends on CD36 and the downstream target ERK, but is
independent of SRC [36]. We found that ERK kinase inhibitor
(PD98059) has no effect on KODA-PC induced P-selectin
expression in human platelets (Figure S6 in File S1). As we
showed above, platelet activation by KODA-PC is SRC depen-
dent. Therefore, oxPCCD36 activate both macrophages and
platelets through CD36, but the downstream signaling cascades
are different. In sum, we found that signaling through SFK, SYK,
and PLCc2 is required for platelet activation by oxPCCD36.
KODA-PC induces the phosphorylation of SYK and PLCc2
via the scavenger receptor CD36 and SFK
We have previously shown that oxPCCD36 activates platelets in
a CD36 dependent manner [3]. Accordingly, we next tested
whether changes in SYK and PLCc2 phosphorylation induced by
KODA-PC and detected by mass spectrometry are CD36
dependent. Anti-CD36 blocking antibody significantly suppressed
the KODA-PC induced phosphorylation of SYK at Tyr323 and
PLCc2 at Tyr1217, while a negative control antibody had no
effect (Figure 5A). This result confirms our mass spectrometry
Figure 1. Phosphoproteomic analysis of platelets activated by the oxidized phospholipid KODA-PC and thrombin. Human platelets
isolated by gel filtration were incubated with the oxidized phospholipid KODA-PC, or PLPC (as control). Platelets were then lysed and the proteins
digested with trypsin. Phospho-tyrosine peptides were enriched from tryptic peptides with 4G10 antibody followed by metal affinity enrichment
(IMAC). The supernatant leftover after immunoprecipitation was fractionated by Strong Cation Exchange (SCX) to separate phospho-serine/threonine
peptides from unphosphorylated peptides. Fractions collected by SCX were further enriched for phosphopeptides using TiO2 metal affinity.
Phosphopeptide-enriched samples were analyzed by LC-MS/MS for identification and quantitation. A detailed description of the method can be
found in the Materials and Methods S1. Differences in protein phosphorylation between platelets incubated with KODA-PC and PLPC as determined
by the phosphoproteomic method were used for analysis at the peptide level (Motif-X), protein level (GO-term, KEGG-pathway, and Kinase
enrichment analysis-KEA), and compared to databases relevant to platelet biology. The same methodology was employed to study differences in
protein phosphorylation between thrombin-induced and resting platelets.
doi:10.1371/journal.pone.0084488.g001
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observations and provides evidence for the requirement of CD36
for SYK and PLCc2 phosphorylation induced by KODA-PC in
platelets.
We next studied the sequence of phosphorylation events
induced by KODA-PC using specific pharmacological inhibitors.
Specific platelet agonists (collagen, CRP, and rhodocytin) activate
platelets through sequential activation of SFK, SYK, and PLCc2.
We investigated if the same downstream pathway takes place in
platelets activated by oxidized phospholipids. KODA-PC induces
strong phosphorylation of the SRC tyrosine residue (Tyr416 in
SRC) (Figure S7 in File S1), an autophosphorylation event known
to increase the activity of the kinase [37]. This phosphorylation is
Figure 2. Distribution of changes in phosphorylation sites induced by KODA-PC and/or thrombin. (A) Common phosphorylation sites
induced by KODA (x-axis; log2 fold change KODA/PLPC) and/or thrombin (y-axis; log2 fold change Thrombin/Resting). Only data with a significant
change in phosphorylation induced by any agonist is shown. If peak ratio was ‘‘.10’’ or ‘‘,0.1’’ in Table S1 in File S2 (indicating a strong
(de)phosphorylation) an arbitrary value of 50 (or 0.02) was assigned and the log2 calculated for graphical representation purpose, (B) Hierarchical
clustering of phosphorylation sites with differences in platelets activated by KODA-PC and thrombin. Each row of the heatmap depicts an individual
phosphorylation event, and each column represents the log2 fold change in phosphorylation induced by KODA-PC or thrombin compared to their
proper control. In the heatmap, red and green represent levels of high and low phosphorylation respectively.
doi:10.1371/journal.pone.0084488.g002
Platelet Activation by oxPCCD36 and Thrombin
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strongly inhibited by the SFK inhibitor PP2. Inhibition of SFK by
PP2 prevented the phosphorylation of SYK at Tyr525/526 and
PLCc2 at Tyr759, and Tyr1217 induced by KODA-PC
(Figure 5B). We also found that SYK inhibitor BAY61-3606
hinders phosphorylation of the downstream target of SYK, PLCc2
at Tyr759 and Tyr1217 induced by KODA-PC (Figure 5B). SYK
inhibitor also diminished the phosphorylation of SYK in the
activation loop (Tyr525/526) (Figure 5B). These results demon-
strate that activation of platelets induced by oxPCCD36 binding to
CD36 leads to a cascade of phosphorylation initiated by SFK,
followed by phosphorylation of SYK at Tyr323 and Tyr525/526.
Phosphorylation of SYK is in turn followed by phosphorylation of
PLCc2 at Tyr759 and Tyr1217. Similar results were obtained
with extended incubation time of platelets with KODA-PC
indicating a sustained activation for up to 30 min (Figure S8 in
File S1).
We tested if KODA and thrombin in combination with the
chemical inhibitors of Src-kinase (PP2), SYK (BAY61-3606), or the
blocking antibody to CD36 had any effect on the cell surface
expression levels of CD41 (integrin a2b) and CD61 (integrin b3).
We found that none of the agonist/inhibitor combinations had an
effect in the levels of CD41 and CD61 in human platelets
measured by flow cytometry (Figure S9 in File S1). Furthermore,
KODA-PC induced changes in phosphorylation of proteins that
participate in the integrin adhesome (Figure S10 in File S1) with
similar trends as those found in platelet activation by thrombin.
These results rule out that KODA activates platelets through an
increase in cell surface expression of integrin a2bb3 or that the
inhibitors work through an indirect mechanism that would
decrease integrin a2bb3 cell surface expression.
Discussion
Phosphoproteomic analysis has been successfully used for the
analysis of the proteome of resting platelets, as well as for the
analysis of the GP-VI mediated platelet activation [38–40].
However, many major pathways of platelet activation are still
not investigated by this approach. In the current study, we
employed a system-wide screen of protein phosphorylation by
mass spectrometry to detect phosphoproteome changes induced
by oxPCCD36, a product of phospholipid oxidation inducing
platelet hyper-reactivity in hyperlipidemia, and thrombin, a strong
platelet agonist. It is important to point out we performed a single
experiment for each agonist and all results presented here are
candidates that require further biological validation. The total
number of phosphorylated proteins detected in the current study is
comparable to previous phosphoproteomic studies in platelets
[26,38,39], but comparison of the phosphorylation sites (Table S6
in File S2) shows only 256 sites overlap between our study and the
most extensive study on platelet phosphoproteomics [26]. This
may be an indication that our phosphoproteomic screen is biased
towards the most abundant phosphopeptides when platelets are
Table 1. Motifs extracted from significantly (de)phosphorylated sites induced by KODA-PC or thrombin.
KODA-PC - Phosphorylation
Motif1 Known substrate/binding2 Proteins with motif phosphorylated
PXXXt Unknown G6B,TMSB4X,UBE2O,DYNC1LI1,MYL12B
RXXs Calmodulin-dependent protein kinase II,
PKA, PKC kinase substrate motif, 14-3-3 domain
binding motif
ZNF185,ZDHHC5,WIPF1,TGFB1I1,TBC1D15,SYNRG,SPAST,SMTN, SLC9A1,
RTN4,RASGRP2,PTPN12,PRKCD,PRKAR1A,PPP1R12A,MYLK,MYL12B,MRVI1,
IQGAP2,HSPB1,FAM65C,DENND4A,DBNL,CNST, ASAP1,ARHGEF6
sP ERK 1/2 kinase substrate motif, WW domain
binding motif
ZYX,ZNF185,USP15,TGFB1I1,SLAIN2,RGC32,PDLIM1,PCBP1,MRVI1,
MAVS,MAP4,LIMA1,LGALSL,INF2,HMHA1,G6B,EPB49,DNM1L,CTTN,CASS4,ASAP1
Thrombin - Phosphorylation
Motif1 Known substrate/binding2 Proteins with motif phosphorylated
RXXs Calmodulin-dependent protein kinase II,
PKA, PKC kinase substrate motif, 14-3-3 domain
binding motif
ZNF185,TBC1D15,SLC9A1,SLC9A1,SH3KBP1,SEPT5,PTPN12,PRKCD,
PITPNM2,PEA15,NCK1,MYLK,MYL12B,MRVI1,HSPB1,HSPB1,FRMD4B,
EPB49,EIF4G1,C10orf54,ASAP1,AMPD2,ADCY6
sP ERK 1/2 kinase substrate motif, WW domain
binding motif
ZYX,ZNF185,WIPF1,WDR44,USP15,TSC22D3,TGFB1I1,SEPT5,SAMD14,MAVS,
LGALSL,KIAA0528,KALRN,FYB,FHOD1,FAM63A,EPB49,
DNM1L,CTTN,CDC42BPB,BIN2,ASAP1,ARHGAP1,ADCY6
y[E/D] Src kinase substrate motif TPM3,SYK,STK4,
PDLIM1,NCK1,INPP5D,FERMT3,DOK1,DAPP1,CTTN,
CFL1,CD84,CASS4,BTK
RXXsL Same as RXXs WIPF1,TSC22D3,TREML1,TJAP1,TGFB1I1,TAOK1,SPN,SPAG9,RIPK1, RASGRP2,
RAB7A,PLA2G4A,MYCT1,MTMR12,MRVI1,MPP1,KLC1,F2R3,DAB2,BIN2
PXsP GSK-3, ERK 1/2, and CDK5 kinase substrate
motif, WW domain binding motif
WIPF1,TSC22D3,TGFB1I1,STIM1,SAMD14,MAVS,FHOD1,FAM63A,
EPB49,EPB49,DNM1L,CTTN,ASAP1,ADCY6
tP WW domain binding motif SPAG9,PTK2B,NBEAL2,CASS4
Thrombin – Dephosphorylation
Motif1 Known substrate/binding2 Proteins with motif dephosphorylated
sP ERK 1/2 kinase substrate motif, WW domain
binding motif
TNIK,STK10,STIM1,SSFA2,SELP,SDPR,PEAR1,MPP1,HMHA1,ASAP1
sXXN Unknown SSFA2,PRKCQ,PRKCD,PRKCB,FRMD4B,DENND2C
1Motif extracted using web-based software Motif-X (reference 29). Phosphorylated residues are indicated as ‘‘s’’, ‘‘t’’, or ‘‘y’’. ‘‘X’’ represents any amino acid.
2Assignment of substrate or binding motif based on PhosphoMotif Finder (reference 30)
doi:10.1371/journal.pone.0084488.t001
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activated by an agonist. Information on changes in phosphoryla-
tion levels at specific sites induced by agonists is less common at
the moment [40] due to the challenges of agonist-platelet
experiments with large scale sampling. The analysis of our data
revealed numerous phosphorylation events that occurred in
proteins whose platelet-related function has just recently been
recognized or is not known indicating the discovery aspect of the
approach and the relevance of the results. For example, both
agonists studied induced significant changes in phosphorylation
sites of SEPT5 and FERMT3, and deficiency of these proteins
causes bleeding disorders associated with platelet defects [41,42].
Also, KODA-PC induced dephosphorylation of LRRFIP1 at
Ser115, a protein with variations in human platelets that affects
platelet reactivity and is associated with myocardial infarction
[43]. Both agonists induced strong phosphorylation changes in
proteins with unknown function in platelets such as HMHA1
(Minor histocompatibility protein HA-1), LGALSL (Galectin-
related protein), or ZNF185 (Zinc finger protein 185).
The current study provides new information on 334 phosphor-
ylation sites of 181 proteins induced in platelets activated by
thrombin. Many phosphorylation responses and pathways inferred
from the bioinformatic analysis are in agreement with known
pathways activated by thrombin, such as changes in cell shape,
protein kinase C, or MAP kinase activation [44]. We focused on
the phosphoproteome network associated with integrin activation
because of its critical function in platelets and the absence of
comprehensive data on site-specific phosphorylation induced by
thrombin or other platelet agonists. One of the informative
findings was changes in phosphorylation status of multiple sites of
talin, filamin, and kindlin-3. Changes in these sites are likely to
induce conformational changes of the proteins or their binding to
target regulators, thereby contributing to the ability of these
proteins to regulate integrin a2bb3 [45]. We also identified a large
number of Src-kinase substrates through Motif-X that are
phosphorylated after activation of platelets by thrombin. These
phosphorylation events do not participate in the initial activation
by thrombin (Src-kinase inhibitor PP2 did not block platelet
activation by thrombin) but may be important in later stages of
platelet regulation and aggregation.
Platelet activation by KODA-PC was used as a model for the
activation of platelets by pro-thrombotic oxidized phospholipids.
We identified changes in protein phosphorylation of 115 proteins
in platelets stimulated by KODA-PC. One of the consensus motifs
(PXXXt) extracted from upregulated phosphorylation events has
not been previously reported in the literature. The closest
reference is a motif (PXXX[t/s]XXC) present in peroxiredoxins
with antioxidant properties [46], but none of the proteins detected
in our results contained the Cys at +3 associated with the
enzymatic activity. From our phosphoproteomic/bioinformatic
analysis, we identified a candidate mechanism for platelet
activation by oxidized phospholipids that includes SFK, SYK,
and PLCc2. Ex vivo validation experiments (Figure 4 and Figure 5)
Figure 3. Phosphoproteome network regulating integrin in platelets activated by thrombin. Proteins and their sites of phosphorylation
identified by mass spectrometry were mapped onto an integrin protein- interaction network (reference 32) as described in Materials and Methods S1.
Graphical representation was done with Cytoscape. Proteins are colored based on the changes in phosphorylation (yellow circle for at least one
phosphorylation event induced by thrombin; white circle for no measurable change by thrombin). Phosphorylation sites are colored based on the up-
regulation (red diamond), down-regulation (green diamond), or absence of modification (white diamond) by thrombin.
doi:10.1371/journal.pone.0084488.g003
Platelet Activation by oxPCCD36 and Thrombin
PLOS ONE | www.plosone.org 7 January 2014 | Volume 9 | Issue 1 | e84488
confirmed that the SFK-SYK-PLCc2 pathway is downstream of
the scavenger receptor CD36 and functions as a signaling axis for
platelet activation by oxPCCD36.
Comparison of our mass spectrometry results (Table S1 in File
S2) to previous reports on platelet activation by collagen and
regulation by SYK allows us to expand the signaling network
beyond the core pathway formed by SFK, SYK, and PLCc2. The
proteins previously described in platelet activation include
FCER1G [35], LY6G6F [28], FLNA [47], G6B [48], FES [49],
PRKCQ [50], OSTF1 [28], and PTPRJ [51]. FCER1G is
Table 2. Phosphorylation dependent responses in integrin b3 adaptor proteins observed in platelets activated by thrombin.
Protein name Gene symbol Tryptic peptide1 Phosphorylation site Fold change2
Kindlin-3 FERMT3 TASGDpYIDSSWELR Y11 .10
EKEPEEELpYDLSK Y162 1.94
LEGpSAPTDVLDSLTTIPELK S337 5
TGpSGGPGNHPHGPDASAEGLNPYGLVAPR S484 .10
TGSGGPGNHPHGPDApSAEGLNPYGLVAPR S497 .10
TGSGGPGNHPHGPDASAEGLNPpYGLVAPR Y504 4.06
Talin TLN1 IGITNHDEpYSLVR Y127 2.5
AVSSAIAQLLGEVAQGNENpYAGIAAR Y1116 .10
TLAESALQLLpYTAK Y1777 .10
Filamin FLNA AFGPGLQGGSAGpSPAR S1084 1.58
VGpSAADIPINISETDLSLLTATVVPPSGR S1967 2.4
Docking protein 1 DOK1 ADpSHEGEVAEGKLPSPPGPQELLDSPPALYAEPLDSLR S269 1.70
KKPLYWDLpYEHAQQQLLK Y341 2.78
Plectin PLEC SSpSVGSSSSYPISPAVSR S4386 5.04
Tyrosine-protein kinase SYK SYK QESTVSFNPpYEPELAPWAADK Y323 .10
Tensin-1 TNS1 VATTPGpSPSLGR S1269 0.61
Disabled homolog 2 DAB2 QVpSLPVTK S723 10.16
Protein-tyrosine kinase 2-beta PTK2B YIEDEDpYpYKASVTR Y579, Y580 .10
YIEDEDYpYKASVTR Y580 6.75
SPLpTPEKEVGpYLEFTGPPQKPPR T842, Y849 .10
1Phosphorylation at tyrosine, serine, or threonine is indicated by ‘‘pY’’, ‘‘pS’’, and ‘‘pT’’ respectively.
2Calculated as the peak area ratio of the tryptic peptide between Thrombin and Resting samples. The largest fold change is shown for peptides with the same sequence
but different charge as shown in Table S1 in File S2.
doi:10.1371/journal.pone.0084488.t002
Figure 4. KODA-PC induces platelet P-selectin expression in a SFK- and SYK-dependent manner. (A-B) Human platelets isolated by gel
filtration were incubated with 10 mM SFK inhibitor (PP2), 0.2 mM SYK inhibitor (BAY 61-3606), or controls (DMSO and 10 mM PP3) for 30 min. Then,
30 mM PLPC, 30 mM KODA-PC, 10 mM ADP, or 0.05 U/mL thrombin were added for 30 min. Platelet P-selectin expression was determined by flow
cytometry using PE-conjugated antibody to P-selectin. (A) Flow cytometry histograms from representative experiments are shown. (B) Quantitation
of flow cytometry data presented as mean 6 SD of at least 3 independent experiments. * P,0.05.
doi:10.1371/journal.pone.0084488.g004
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particularly interesting because it contains an ITAM-motif that
allows SYK binding and activation [52]. Other phosphorylation
events relate to inhibitory mechanisms that may prevent strong
platelet activation by KODA-PC. For instance, KODA-PC
induces phosphorylation of PKCd (PRKCD) at Ser304 and
Tyr313, a protein that prevents granule secretion by collagen [53].
Phosphorylation of PKCd at Tyr313 (indicated as Tyr311 in many
publications) is important for its activity [54]. Rottlerin, an
inhibitor to PKCd, enhanced P-selectin expression in human
platelets induced by KODA-PC (data not shown), suggesting that
PKCd indeed down-regulates platelet activation by oxidized
phospholipids. Similarly, MRVI1 (or IRAG) is involved in platelet
regulation, and mouse models lacking this protein have increased
platelet aggregation in response to thrombin and collagen [55].
Platelet shape change, a critical part of platelet activation,
depends on actin polymerization leading to the formation of a
variety of higher order cytoplasmic structures involved into the
formation of filopodia, lamellipodia and eventual spreading on the
surface of adhesive substrate. A large number of actin-binding
proteins regulate actin assembly and disassembly. Interestingly, we
observed that KODA significantly and specifically regulates a
number of actin binding proteins known to play a role in
thrombosis. These include filamin A, supervillin, and non-muscle
myosin heavy chain 9. Filamin A, an actin binding protein
crosslinking F-actin fibers, is known to bind to the cytoplasmic tail
of b-integrins and to coordinate the interaction between integrins
and the cytoskeleton. Alterations in platelet function in patients
with filamin A mutations are reported [56]. Cytoskeletal
regulatory protein supervillin may serve as a high-affinity link
between the actin cytoskeleton and the membrane. Its expression
negatively regulates platelet reactivity and thrombus formation
[57]. Non-muscle myosin heavy chain 9 plays a key role in platelet
contractile phenomena and outside-in signaling [58]. Several actin
binding proteins with a function not yet demonstrated in platelets
are also affected by KODA. These include nexilin, which binds to
F-actin and may function in cell adhesion adhesion, derbin-like
protein, which participates in lamellipodia formation, dystonin, a
protein connecting intermediate filaments to actin, and LIMA1
(eplin), an inhibitor of actin filament depolymerization. Taken
together, these data suggest that specific oxidized phospholipids
ligands for CD36 induce a disproportionally strong effect on
platelet cytoskeleton.
Throughout this paper, we have described the role of Src family
kinases (SFK) without assigning the specific member(s) of the
family. Western blotting analysis detected an increase in
phosphorylation of several bands corresponding to members of
the SFK (Figure S7 in File S1). LYN and FYN, members of the
SFK, associate to CD36 when platelets are activated by oxLDL, a
lipoprotein containing oxidized phospholipids [12]. Even though
LYN is the most important SFK in platelet activation by agonists
such as collagen, double knockout combinations of LYN and
another SFK are more effective to delay platelet activation and
inhibit FCER1G phosphorylation than single knock out of LYN in
mice [59]. Therefore, it seems reasonable to hypothesize over-
lapping roles for members of the SFK in initiating platelet acti-
vation by oxPCCD36 that will need to be elucidated in future studies.
Previous reports demonstrated that CD36 is required for
induction of apoptosis in macrophages by oxidized phospholipids
[36]. Activation in macrophages requires ERK and is independent
of SFK. In contrast, the activation of platelets by oxPCCD36
requires CD36 and SFK but it is independent of ERK (Figure S6
in File S1). In aortic endothelial cells, both SFK and ERK are key
in the signaling cascade induced by oxidized products of PAPC
[22,60]. Lack of CD36 participation in aortic endothelial cell
activation by oxidized PAPC [61] further extends the divergence
in signal mechanisms elicited by the same ligands in endothelial
cells, platelets, and macrophages, representing different cell types
with prominent roles in cardiovascular disease. These differences
can help guide specifically targeted kinase inhibitor-based thera-
peutic approaches. Taken together, our results provide insights
into the mechanism of platelet activation by oxidized phospholip-
ids, compounds generated in conditions of hyperlipidemia and
oxidative stress and modulating platelet function in vivo.
Supporting Information
File S1 Figure S1. KODA-PC induces the phosphorylation of
numerous proteins in human platelets. Figure S2. Abundance of
proteins identified by phosphoproteomics in platelets based on
Burkhart et al (Blood, 120: e73-82, 2012). Figure S3. Motif-X
analysis of sites that were (de)phosphorylated after platelet
activation by KODA-PC and thrombin. Figure S4. Selected
GO-terms enriched from the list of genes identified by phospho-
proteomic in platelets activated by KODA-PC and thrombin.
Figure 5. KODA-PC activates the sequential phosphorylation of
SFK, SYK, and PLCc2 through CD36. (A) Human platelets isolated
by gel filtration were incubated with buffer alone (–), CD36 blocking
antibody clone FA6-152 (CD36), or a negative control antibody (IgG);
then, 50 mM PLPC or 50 mM KODA-PC were added to the platelets for 7
minutes. Equal amount of protein were separated by gel electropho-
resis and probed with antibodies raised against phosphorylated SYK
(pTyr323) and PLCc2 (pTyr1217). The blots were reprobed with SYK and
PLCc2 antibodies for normalization. (B) Human platelets isolated by gel
filtration were incubated with DMSO, 10 mM SFK inhibitor (PP2), or
0.2 mM SYK inhibitor (BAY61-3606) for 30 min; then, 50 mM PLPC or
50 mM KODA-PC were added to the platelets for 7 minutes. Equal
amount of protein were separated by gel electrophoresis and probed
with antibodies raised against phosphorylated SYK (pTyr525/526) and
PLCc2 (pTyr759 and pTyr1217). The blots were reprobed with SYK and
PLCc2 antibodies for normalization.
doi:10.1371/journal.pone.0084488.g005
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induced by different ligands. Figure S6. ERK kinase is not
required for P-selectin expression induced by KODA-PC. Figure
S7. KODA-PC induces Src-family kinases (SFK) phosphorylation.
Figure S8. SYK and PLCc2 phosphorylation induced by
KODA-PC at different time points in the presence of CD36
blocking antibody and chemical inhibitors to SFK and SYK.
Figure S9. Surface level expression of CD41 and CD61 is not
affected by KODA-PC, thrombin, chemical inhibitors PP2 and
BAY61-3606, or blocking antibody to CD36. Figure S10.
Phosphoproteome network regulating integrin in platelets activat-
ed by KODA-PC.
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